Yarrow Bioscience (NASDAQ:YARW – Get Free Report) and ADC Therapeutics (NYSE:ADCT – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, earnings, valuation, profitability, analyst recommendations and risk.
Profitability
This table compares Yarrow Bioscience and ADC Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Yarrow Bioscience | -4,726.21% | -84.40% | -77.68% |
| ADC Therapeutics | -121.77% | N/A | -32.74% |
Volatility & Risk
Yarrow Bioscience has a beta of 2.1, meaning that its stock price is 110% more volatile than the S&P 500. Comparatively, ADC Therapeutics has a beta of 1.82, meaning that its stock price is 82% more volatile than the S&P 500.
Earnings & Valuation
This table compares Yarrow Bioscience and ADC Therapeutics”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Yarrow Bioscience | $570,000.00 | 82.91 | -$26.48 million | ($14.64) | -1.21 |
| ADC Therapeutics | $81.36 million | 2.91 | -$142.62 million | ($0.66) | -2.81 |
Yarrow Bioscience has higher earnings, but lower revenue than ADC Therapeutics. ADC Therapeutics is trading at a lower price-to-earnings ratio than Yarrow Bioscience, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a summary of current ratings and target prices for Yarrow Bioscience and ADC Therapeutics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Yarrow Bioscience | 1 | 0 | 2 | 0 | 2.33 |
| ADC Therapeutics | 1 | 2 | 3 | 0 | 2.33 |
Yarrow Bioscience presently has a consensus price target of $58.00, suggesting a potential upside of 227.68%. ADC Therapeutics has a consensus price target of $5.00, suggesting a potential upside of 169.98%. Given Yarrow Bioscience’s higher possible upside, equities research analysts clearly believe Yarrow Bioscience is more favorable than ADC Therapeutics.
Insider & Institutional Ownership
83.8% of Yarrow Bioscience shares are owned by institutional investors. Comparatively, 41.1% of ADC Therapeutics shares are owned by institutional investors. 3.0% of Yarrow Bioscience shares are owned by company insiders. Comparatively, 5.1% of ADC Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Summary
ADC Therapeutics beats Yarrow Bioscience on 7 of the 13 factors compared between the two stocks.
About Yarrow Bioscience
VYNE Therapeutics Inc., a pharmaceutical company, focuses on developing various therapeutics for the treatment of immuno-inflammatory conditions. The company develops FCD105, a topical combination foam that has completed Phase III clinical trials for the treatment of moderate-to-severe acne vulgaris; and FMX114, a combination of tofacitinib, which is in Phase IIa preclinical trial for the treatment of mild-to-moderate atopic dermatitis. It is also developing VYN201, a bromodomain and extra-terminal (BET) inhibitor for various immuno-inflammatory diseases, including skin diseases; and VYN202, BET inhibitor compounds that are selective for bromodomain 2. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.
About ADC Therapeutics
ADC Therapeutics SA focuses on advancing its proprietary antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product is ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is also seeking to continue expanding ZYNLONTA into international markets and into earlier lines of DLBCL and indolent lymphomas, including follicular lymphoma (FL) and marginal zone lymphoma (MZL) as a single agent and in combination through its LOTIS-5 confirmatory Phase 3 clinical trial and LOTIS-7 Phase 1b clinical trial, as well as through investigator-initiated trials (IITs). In addition, it is investigating a CD-22 targeted compound, ADCT-602 that is in a Phase 1/2 investigator-initiated study in relapsed or refractory B-cell acute lymphoblastic leukemia. Further, its clinical-stage pipeline consists of ADCT-601 (mipasetamab uzoptirine) targeting AXL as a single agent and/or in combination in sarcoma, pancreatic, and NSCLC, as well as pre-clinical stage pipeline includes a portfolio of next generation investigational ADCs targeting Claudin-6, NaPi2b, PSMA, and other undisclosed targets. The company was incorporated in 2011 and is headquartered in Epalinges, Switzerland.
Receive News & Ratings for Yarrow Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Yarrow Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.
